Phase I Trial of Weekly and Twice-Weekly Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Relapsed or Refractory Non–Hodgkin Lymphoma-Reference-Cited by-同舟云学术

Phase I Trial of Weekly and Twice-Weekly Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Relapsed or Refractory Non–Hodgkin Lymphoma

Published:2011-02-23 Issue:8 Volume:17 Page:2493-2501
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Gerecitano John,Portlock Carol,Hamlin Paul,Moskowitz Craig H.,Noy Ariela,Straus David,Schulman Philip,Dumitrescu Otilia,Sarasohn Debra,Pappanicholaou Jennifer,Iasonos Alexia,Zhang Zhigang,Mo Qianxing,Horanlli Endri,Rojas Celeste N.,Zelenetz Andrew D.,O'Connor Owen A.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomaterial-Based Sustained-Release Drug Formulations for Localized Cancer Immunotherapy;ACS Applied Bio Materials;2023-12-05

2. New trends in synthetic drugs and natural products targeting 20S proteasomes in cancers;Bioorganic Chemistry;2023-04

3. Clinical Experience on Proteasome Inhibitors in Cancer;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15

4. Efficacy and Safety of Once‐Weekly versus Twice‐Weekly Bortezomib in Patients with Hematologic Malignancies: A Meta‐analysis with Trial Sequential Analysis;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2019-05-08

5. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma;Cancer;2018-05-03